Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx, Inc. (Nasdaq: ARDX) has published plain language summaries of two clinical trials for XPHOZAH® (tenapanor) in Current Medical Research and Opinion. These summaries, from the NORMALIZE and OPTIMIZE studies, aim to help patients with chronic kidney disease on dialysis understand the safety and efficacy data of XPHOZAH. The FDA-approved drug is the first and only phosphate absorption inhibitor designed to reduce serum phosphorus in adult CKD patients on dialysis. It's used as an add-on therapy for patients with inadequate response to or intolerance of phosphate binders. XPHOZAH's unique mechanism blocks phosphate absorption at the primary pathway and is administered as a single tablet twice daily. The summaries provide accessible information about XPHOZAH's potential impact on lowering serum phosphorus levels, helping patients and caregivers make informed decisions about treatment options.
Ardelyx (Nasdaq: ARDX) has announced a conference call scheduled for August 1, 2024, at 4:30 p.m. Eastern Time to discuss its second quarter 2024 financial results and provide a business update. Interested parties can participate by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) and asking to join the Ardelyx call. A live audio webcast will be available on the company's website under the Investors section, with a 30-day archive available after the call. Ardelyx is a biopharmaceutical company focused on developing innovative, first-in-class medicines for significant unmet medical needs.
Ardelyx, along with AAKP and NMQF, has filed a lawsuit against the U.S. Department of Health and Human Services and CMS. The lawsuit challenges CMS's plan to include XPHOZAH and other oral-only phosphate lowering therapies (PLTs) in the End-Stage Renal Disease Prospective Payment System (ESRD PPS).
The plaintiffs argue that this move violates statutory authority under MIPPA and will negatively impact patient choice and timely access to important medications. They seek to prevent CMS from including XPHOZAH in the ESRD PPS and eliminating coverage under Medicare Part D starting January 1, 2025.
XPHOZAH, approved by the FDA in October 2023, is a first-in-class phosphate absorption inhibitor for adults with chronic kidney disease on dialysis. The lawsuit aims to protect dialysis patients' access to new therapies and maintain incentives for developing innovative medicines in this underserved therapeutic area.
Ardelyx has decided not to apply for the CMS TDAPA for its phosphate absorption inhibitor, XPHOZAH (tenapanor), to maintain patient access. The company supports bipartisan legislation that aims to extend the exclusion of oral-only medications from the CMS Prospective Payment System. This decision follows Ardelyx's analysis of the CMS policy, determining that including XPHOZAH in the Medicare PPS would significantly restrict its usage and hinder patient access. XPHOZAH, approved by the FDA in October 2023, is the only therapy for patients with inadequate response to phosphate binders, offering a unique mechanism to reduce serum phosphorus in CKD patients on dialysis. A conference call is scheduled for July 2, 2024, at 8:00 AM ET to discuss the announcement.
Ardelyx (Nasdaq: ARDX) presented new data on the educational needs related to the management of irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference.
The findings, based on a survey of 410 healthcare professionals, highlighted significant differences in diagnostic criteria, testing methodologies, referral tendencies, and pain assessment approaches between nurse practitioners/physician assistants and physicians.
Additionally, the data showed that gastroenterology specialists are more likely to prescribe medications like linaclotide, plecanatide, or tenapanor for IBS-C patients avoiding social events due to discomfort, whereas primary care physicians prefer neuromodulators.
These insights underscore the need for tailored educational programs to address the specific requirements of various healthcare roles.
Ardelyx (Nasdaq: ARDX), a biopharmaceutical company, announced on May 30, 2024, that its compensation committee granted stock options and Restricted Stock Units (RSUs) to 23 new non-executive employees on May 23, 2024. A total of 210,000 stock options and 179,050 RSUs were awarded. The options have an exercise price of $7.44 per share, reflecting the closing price on the grant date. Both stock options and RSUs vest over four years with specific vesting schedules. These grants were made under Nasdaq Listing Rule 5635(c)(4) to incentivize employment.
Ardelyx, a biopharmaceutical company (Nasdaq: ARDX), will participate in the 2024 Jefferies Global Healthcare Conference. Michael Raab, President and CEO, alongside Justin Renz, Chief Financial and Operations Officer, will engage in a fireside chat on June 5, 2024, at 10:00 A.M. Eastern Time in New York City. The event will be accessible via live webcast on the Ardelyx website, with a replay available for 30 days after the event.
Ardelyx, a biopharmaceutical company, announced additional positive clinical data for IBSRELA® (tenapanor) at the 2024 Digestive Disease Week Conference in Washington, D.C. IBSRELA, approved by the FDA for treating irritable bowel syndrome with constipation (IBS-C) in adults, demonstrated a clinically meaningful response in a Phase 3 post hoc analysis. The treatment proved effective regardless of prior use of other IBS-C medications and showed comparable or more pronounced efficacy in Hispanic patients. These findings further support IBSRELA's potential as a novel treatment option for IBS-C.
Ardelyx (Nasdaq: ARDX) presented new data on XPHOZAH® (tenapanor) at the NKF 2024 Spring Clinical Meetings. The drug, approved by the FDA, helps reduce serum phosphorus in CKD patients on dialysis. Presented posters showed improved phosphate control when tenapanor was added to existing treatments, effective results across various age groups, and increased patient adherence due to improved treatment perception. These findings, highlighting XPHOZAH's unique mechanism of action, were shared during an Exhibitor Showcase discussing hyperphosphatemia management.
Ardelyx, a biopharmaceutical company, announced on May 6, 2024, the granting of stock options and Restricted Stock Units (RSUs) to new non-executive employees. The compensation committee approved options for 26 employees, totaling 511,500 shares, and RSUs for 32 employees, totaling 425,050 shares. The stock options have an exercise price of $9.15 per share, the closing price on the grant date, and vest over four years. RSUs also vest over four years, with specific quarterly vesting schedules. These inducements align with Nasdaq Listing Rule 5635(c)(4) and are part of Ardelyx's 2016 Employment Commencement Incentive Plan.